25 XP   0   0   10

BioArctic AB (publ)
Buy, Hold or Sell?

Let's analyse Bioarctic together

PenkeI guess you are interested in BioArctic AB (publ). Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of BioArctic AB (publ). At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about BioArctic AB (publ)

I send you an email if I find something interesting about BioArctic AB (publ).

Quick analysis of Bioarctic (30 sec.)










What can you expect buying and holding a share of Bioarctic? (30 sec.)

How much money do you get?

How much money do you get?
kr0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
kr11.85
Expected worth in 1 year
kr14.84
How sure are you?
40.0%

+ What do you gain per year?

Total Gains per Share
kr2.99
Return On Investment
1.5%

For what price can you sell your share?

Current Price per Share
kr202.40
Expected price per share
kr110.60 - kr245.40
How sure are you?
50%

1. Valuation of Bioarctic (5 min.)




Live pricePrice per Share (EOD)

kr202.40

Intrinsic Value Per Share

kr65.95 - kr79.25

Total Value Per Share

kr77.81 - kr91.10

2. Growth of Bioarctic (5 min.)




Is Bioarctic growing?

Current yearPrevious yearGrowGrow %
How rich?$96.1m$70.5m$27.2m27.9%

How much money is Bioarctic making?

Current yearPrevious yearGrowGrow %
Making money$5.2m-$261k$5.5m105.0%
Net Profit Margin-1,109.5%-1,244.2%--

How much money comes from the company's main activities?

3. Financial Health of Bioarctic (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#381 / 1019

Most Revenue
#270 / 1019

Most Profit
#114 / 1019

Most Efficient
#820 / 1019

What can you expect buying and holding a share of Bioarctic? (5 min.)

Welcome investor! Bioarctic's management wants to use your money to grow the business. In return you get a share of Bioarctic.

What can you expect buying and holding a share of Bioarctic?

First you should know what it really means to hold a share of Bioarctic. And how you can make/lose money.

Speculation

The Price per Share of Bioarctic is kr202.40. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Bioarctic.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Bioarctic, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is kr11.85. Based on the TTM, the Book Value Change Per Share is kr0.75 per quarter. Based on the YOY, the Book Value Change Per Share is kr0.38 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is kr0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Bioarctic.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 kr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Share
Usd Eps-0.090.0%0.060.0%0.000.0%0.010.0%0.020.0%
Usd Book Value Change Per Share-0.090.0%0.070.0%0.040.0%0.000.0%0.040.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.090.0%0.070.0%0.040.0%0.000.0%0.040.0%
Usd Price Per Share24.61-24.91-16.64-13.54-9.86-
Price to Earnings Ratio-67.77--14.93--37.31--34.42--13.72-
Price-to-Total Gains Ratio-282.01--73.98--88.22-90.66--37.30-
Price to Book Ratio22.60-22.54-20.38-14.37-10.64-
Price-to-Total Gains Ratio-282.01--73.98--88.22-90.66--37.30-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share18.60056
Number of shares53
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.070.00
Usd Total Gains Per Share0.070.00
Gains per Quarter (53 shares)3.640.11
Gains per Year (53 shares)14.540.43
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1015500-10
20292001-10
30443501-10
40585002-10
50736502-10
60878003-10
701029503-10
8011611003-10
9013112504-10
10014514004-10

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share2.02.00.050.0%3.09.00.025.0%6.014.00.030.0%14.016.00.046.7%14.016.00.046.7%
Book Value Change Per Share2.02.00.050.0%4.08.00.033.3%6.014.00.030.0%12.016.02.040.0%12.016.02.040.0%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.030.00.0%0.00.030.00.0%
Total Gains per Share2.02.00.050.0%4.08.00.033.3%6.014.00.030.0%12.016.02.040.0%12.016.02.040.0%

Fundamentals of Bioarctic

About BioArctic AB (publ)

BioArctic AB (publ) develops biological drugs for patients with neurodegenerative disorders in Sweden. The company develops Lecanemab, Lecanemab AHEAD 3-45, and Lecanemab Back-up for the treatment of Alzheimer's disease. It also develops ABBV-0805, for treating Parkinson's disease. In addition, the company develops AD-BT2802 and AD-BT2803 drug projects against Alzheimer's disease that are being combined with blood-brain barrier technology and Brain Transporter to promote uptake of antibodies into the brain, as well as focuses on developing ND3014 antibodies for treating neurodegenerative disorders. Further, it develops BAN1503, AD-BT2802, AD-BT2803, AD1502, AD1503, and AD2603 for the treatment of Alzheimer's disease; ND-BT3814 andGD-BT6822 for the treatment of neurodegenerative disease; and PD1601, BAN0805, PD-BT2238, and PD1602 for the treatment of Parkinson's disease. It has research collaboration agreement with Eisai and AbbVie. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.

Fundamental data was last updated by Penke on 2024-03-29 02:49:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of BioArctic AB (publ).

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Bioarctic earns for each kr1 of revenue.

  • Above 10% is considered healthy but always compare Bioarctic to the Biotechnology industry mean.
  • A Net Profit Margin of -791.4% means that kr-7.91 for each kr1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of BioArctic AB (publ):

  • The MRQ is -791.4%. The company is making a huge loss. -2
  • The TTM is -1,109.5%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-791.4%TTM-1,109.5%+318.1%
TTM-1,109.5%YOY-1,244.2%+134.7%
TTM-1,109.5%5Y-627.8%-481.7%
5Y-627.8%10Y-432.2%-195.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-791.4%-196.9%-594.5%
TTM-1,109.5%-211.2%-898.3%
YOY-1,244.2%-279.3%-964.9%
5Y-627.8%-436.8%-191.0%
10Y-432.2%-599.3%+167.1%
1.1.2. Return on Assets

Shows how efficient Bioarctic is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Bioarctic to the Biotechnology industry mean.
  • -7.4% Return on Assets means that Bioarctic generated kr-0.07 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of BioArctic AB (publ):

  • The MRQ is -7.4%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is 4.7%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ-7.4%TTM4.7%-12.0%
TTM4.7%YOY-0.7%+5.3%
TTM4.7%5Y0.2%+4.5%
5Y0.2%10Y1.5%-1.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-7.4%-13.6%+6.2%
TTM4.7%-12.9%+17.6%
YOY-0.7%-11.9%+11.2%
5Y0.2%-14.2%+14.4%
10Y1.5%-16.2%+17.7%
1.1.3. Return on Equity

Shows how efficient Bioarctic is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Bioarctic to the Biotechnology industry mean.
  • -8.3% Return on Equity means Bioarctic generated kr-0.08 for each kr1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of BioArctic AB (publ):

  • The MRQ is -8.3%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is 4.9%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ-8.3%TTM4.9%-13.2%
TTM4.9%YOY-0.9%+5.8%
TTM4.9%5Y0.1%+4.7%
5Y0.1%10Y5.8%-5.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-8.3%-17.0%+8.7%
TTM4.9%-16.1%+21.0%
YOY-0.9%-15.4%+14.5%
5Y0.1%-20.0%+20.1%
10Y5.8%-21.1%+26.9%

1.2. Operating Efficiency of BioArctic AB (publ).

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Bioarctic is operating .

  • Measures how much profit Bioarctic makes for each kr1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Bioarctic to the Biotechnology industry mean.
  • An Operating Margin of -722.5% means the company generated kr-7.23  for each kr1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of BioArctic AB (publ):

  • The MRQ is -722.5%. The company is operating very inefficient. -2
  • The TTM is -1,076.6%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-722.5%TTM-1,076.6%+354.0%
TTM-1,076.6%YOY-1,274.9%+198.3%
TTM-1,076.6%5Y-658.7%-417.8%
5Y-658.7%10Y-434.4%-224.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-722.5%-282.4%-440.1%
TTM-1,076.6%-225.8%-850.8%
YOY-1,274.9%-288.4%-986.5%
5Y-658.7%-475.2%-183.5%
10Y-434.4%-624.7%+190.3%
1.2.2. Operating Ratio

Measures how efficient Bioarctic is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 8.23 means that the operating costs are kr8.23 for each kr1 in net sales.

Let's take a look of the Operating Ratio trends of BioArctic AB (publ):

  • The MRQ is 8.225. The company is inefficient in keeping operating costs low. -1
  • The TTM is 11.778. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ8.225TTM11.778-3.552
TTM11.778YOY12.612-0.835
TTM11.7785Y7.350+4.427
5Y7.35010Y5.419+1.932
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ8.2252.994+5.231
TTM11.7783.247+8.531
YOY12.6123.766+8.846
5Y7.3505.675+1.675
10Y5.4197.857-2.438

1.3. Liquidity of BioArctic AB (publ).

1.3. Liquidity
1.3.1. Current Ratio

Measures if Bioarctic is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 9.22 means the company has kr9.22 in assets for each kr1 in short-term debts.

Let's take a look of the Current Ratio trends of BioArctic AB (publ):

  • The MRQ is 9.224. The company is very able to pay all its short-term debts. +2
  • The TTM is 11.976. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ9.224TTM11.976-2.752
TTM11.976YOY10.338+1.639
TTM11.9765Y9.596+2.380
5Y9.59610Y6.985+2.611
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ9.2243.930+5.294
TTM11.9764.251+7.725
YOY10.3385.436+4.902
5Y9.5966.045+3.551
10Y6.9856.383+0.602
1.3.2. Quick Ratio

Measures if Bioarctic is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Bioarctic to the Biotechnology industry mean.
  • A Quick Ratio of 4.89 means the company can pay off kr4.89 for each kr1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of BioArctic AB (publ):

  • The MRQ is 4.894. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 9.655. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ4.894TTM9.655-4.761
TTM9.655YOY10.220-0.565
TTM9.6555Y9.093+0.562
5Y9.09310Y6.598+2.495
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.8943.629+1.265
TTM9.6554.065+5.590
YOY10.2205.390+4.830
5Y9.0935.993+3.100
10Y6.5986.277+0.321

1.4. Solvency of BioArctic AB (publ).

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Bioarctic assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Bioarctic to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.12 means that Bioarctic assets are financed with 11.8% credit (debt) and the remaining percentage (100% - 11.8%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of BioArctic AB (publ):

  • The MRQ is 0.118. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.089. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.118TTM0.089+0.029
TTM0.089YOY0.100-0.011
TTM0.0895Y0.132-0.044
5Y0.13210Y0.271-0.138
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1180.332-0.214
TTM0.0890.333-0.244
YOY0.1000.268-0.168
5Y0.1320.366-0.234
10Y0.2710.390-0.119
1.4.2. Debt to Equity Ratio

Measures if Bioarctic is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Bioarctic to the Biotechnology industry mean.
  • A Debt to Equity ratio of 13.3% means that company has kr0.13 debt for each kr1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of BioArctic AB (publ):

  • The MRQ is 0.133. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.098. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.133TTM0.098+0.036
TTM0.098YOY0.111-0.013
TTM0.0985Y0.156-0.058
5Y0.15610Y1.496-1.341
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1330.380-0.247
TTM0.0980.389-0.291
YOY0.1110.334-0.223
5Y0.1560.432-0.276
10Y1.4960.465+1.031

2. Market Valuation of BioArctic AB (publ)

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every kr1 in earnings Bioarctic generates.

  • Above 15 is considered overpriced but always compare Bioarctic to the Biotechnology industry mean.
  • A PE ratio of -67.77 means the investor is paying kr-67.77 for every kr1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of BioArctic AB (publ):

  • The EOD is -51.217. Based on the earnings, the company is expensive. -2
  • The MRQ is -67.767. Based on the earnings, the company is expensive. -2
  • The TTM is -14.934. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-51.217MRQ-67.767+16.549
MRQ-67.767TTM-14.934-52.832
TTM-14.934YOY-37.310+22.375
TTM-14.9345Y-34.425+19.490
5Y-34.42510Y-13.721-20.704
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-51.217-2.426-48.791
MRQ-67.767-2.552-65.215
TTM-14.934-2.656-12.278
YOY-37.310-4.143-33.167
5Y-34.425-6.252-28.173
10Y-13.721-6.108-7.613
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of BioArctic AB (publ):

  • The EOD is 38.266. Based on how much money comes from the company's main activities, the company is fair priced.
  • The MRQ is 50.631. Based on how much money comes from the company's main activities, the company is overpriced. -1
  • The TTM is -36.184. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD38.266MRQ50.631-12.365
MRQ50.631TTM-36.184+86.815
TTM-36.184YOY-36.235+0.050
TTM-36.1845Y-52.881+16.696
5Y-52.88110Y-39.881-13.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD38.266-3.199+41.465
MRQ50.631-3.259+53.890
TTM-36.184-3.552-32.632
YOY-36.235-5.617-30.618
5Y-52.881-8.326-44.555
10Y-39.881-8.689-31.192
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Bioarctic is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 22.60 means the investor is paying kr22.60 for each kr1 in book value.

Let's take a look of the Price to Book Ratio trends of BioArctic AB (publ):

  • The EOD is 17.078. Based on the equity, the company is expensive. -2
  • The MRQ is 22.596. Based on the equity, the company is expensive. -2
  • The TTM is 22.535. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD17.078MRQ22.596-5.518
MRQ22.596TTM22.535+0.061
TTM22.535YOY20.380+2.156
TTM22.5355Y14.366+8.169
5Y14.36610Y10.643+3.723
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD17.0781.947+15.131
MRQ22.5962.116+20.480
TTM22.5352.095+20.440
YOY20.3802.836+17.544
5Y14.3663.443+10.923
10Y10.6433.791+6.852
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of BioArctic AB (publ) compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.9500.746-227%0.384-347%0.022-4449%0.395-340%
Book Value Per Share--11.85212.059-2%8.655+37%10.308+15%8.353+42%
Current Ratio--9.22411.976-23%10.338-11%9.596-4%6.985+32%
Debt To Asset Ratio--0.1180.089+33%0.100+18%0.132-11%0.271-57%
Debt To Equity Ratio--0.1330.098+36%0.111+20%0.156-14%1.496-91%
Dividend Per Share----0%-0%-0%-0%
Eps---0.9880.650-252%-0.032-97%0.070-1521%0.221-548%
Free Cash Flow Per Share--1.3220.845+57%-0.089+107%0.195+579%0.262+405%
Free Cash Flow To Equity Per Share--1.3340.885+51%-0.097+107%0.115+1064%0.381+250%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.051-5%
Intrinsic Value_10Y_max--79.246--------
Intrinsic Value_10Y_min--65.954--------
Intrinsic Value_1Y_max--1.585--------
Intrinsic Value_1Y_min--1.553--------
Intrinsic Value_3Y_max--9.607--------
Intrinsic Value_3Y_min--9.074--------
Intrinsic Value_5Y_max--23.468--------
Intrinsic Value_5Y_min--21.366--------
Market Cap14961955289.600-58%23648614600.00023908200087.200-1%16053575142.500+47%13155311006.980+80%9566717482.797+147%
Net Profit Margin---7.914-11.095+40%-12.442+57%-6.278-21%-4.322-45%
Operating Margin---7.225-10.766+49%-12.749+76%-6.587-9%-4.344-40%
Operating Ratio--8.22511.778-30%12.612-35%7.350+12%5.419+52%
Pb Ratio17.078-32%22.59622.535+0%20.380+11%14.366+57%10.643+112%
Pe Ratio-51.217+24%-67.767-14.934-78%-37.310-45%-34.425-49%-13.721-80%
Price Per Share202.400-32%267.800271.050-1%181.063+48%147.365+82%107.247+150%
Price To Free Cash Flow Ratio38.266-32%50.631-36.184+171%-36.235+172%-52.881+204%-39.881+179%
Price To Total Gains Ratio-213.140+24%-282.010-73.977-74%-88.219-69%90.664-411%-37.305-87%
Quick Ratio--4.8949.655-49%10.220-52%9.093-46%6.598-26%
Return On Assets---0.0740.047-257%-0.007-91%0.002-3789%0.015-595%
Return On Equity---0.0830.049-271%-0.009-89%0.001-5813%0.058-244%
Total Gains Per Share---0.9500.746-227%0.384-347%0.022-4449%0.395-340%
Usd Book Value--96180242.50097750974.325-2%70503910.925+36%84479764.250+14%68249761.687+41%
Usd Book Value Change Per Share---0.0870.069-227%0.035-347%0.002-4449%0.036-340%
Usd Book Value Per Share--1.0891.108-2%0.795+37%0.947+15%0.768+42%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.0910.060-252%-0.003-97%0.006-1521%0.020-548%
Usd Free Cash Flow--10731071.1006849582.700+57%-726883.050+107%1585849.375+577%2128554.103+404%
Usd Free Cash Flow Per Share--0.1220.078+57%-0.008+107%0.018+579%0.024+405%
Usd Free Cash Flow To Equity Per Share--0.1230.081+51%-0.009+107%0.011+1064%0.035+250%
Usd Market Cap1375003691.114-58%2173307681.7402197163588.014-1%1475323555.596+47%1208973081.541+80%879181336.669+147%
Usd Price Per Share18.601-32%24.61124.909-1%16.640+48%13.543+82%9.856+150%
Usd Profit---8017631.7005266995.775-252%-261087.900-97%542430.560-1578%1782902.887-550%
Usd Revenue--1013105.60014152462.150-93%5245008.700-81%5567090.630-82%6622470.230-85%
Usd Total Gains Per Share---0.0870.069-227%0.035-347%0.002-4449%0.036-340%
 EOD+4 -4MRQTTM+10 -23YOY+15 -185Y+14 -1910Y+15 -19

3.2. Fundamental Score

Let's check the fundamental score of BioArctic AB (publ) based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-51.217
Price to Book Ratio (EOD)Between0-117.078
Net Profit Margin (MRQ)Greater than0-7.914
Operating Margin (MRQ)Greater than0-7.225
Quick Ratio (MRQ)Greater than14.894
Current Ratio (MRQ)Greater than19.224
Debt to Asset Ratio (MRQ)Less than10.118
Debt to Equity Ratio (MRQ)Less than10.133
Return on Equity (MRQ)Greater than0.15-0.083
Return on Assets (MRQ)Greater than0.05-0.074
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of BioArctic AB (publ) based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose214.600
Total1/1 (100.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Long-term Assets Other  1,60671,613381,651-31,648-1,6480



Latest Balance Sheet

Balance Sheet of 2023-12-31. All numbers in thousands.

Summary
Total Assets1,186,078
Total Liabilities139,503
Total Stockholder Equity1,046,575
 As reported
Total Liabilities 139,503
Total Stockholder Equity+ 1,046,575
Total Assets = 1,186,078

Assets

Total Assets1,186,078
Total Current Assets1,152,739
Long-term Assets33,339
Total Current Assets
Cash And Cash Equivalents 611,567
Other Current Assets 541,172
Total Current Assets  (as reported)1,152,739
Total Current Assets  (calculated)1,152,739
+/-0
Long-term Assets
Property Plant Equipment 31,126
Other Assets 0
Long-term Assets  (as reported)33,339
Long-term Assets  (calculated)31,126
+/- 2,213

Liabilities & Shareholders' Equity

Total Current Liabilities124,966
Long-term Liabilities14,537
Total Stockholder Equity1,046,575
Total Current Liabilities
Short-term Debt 2,827
Accounts payable 73,290
Other Current Liabilities 48,849
Total Current Liabilities  (as reported)124,966
Total Current Liabilities  (calculated)124,966
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)14,537
Long-term Liabilities  (calculated)0
+/- 14,537
Total Stockholder Equity
Common Stock1,766
Other Stockholders Equity 1,044,809
Total Stockholder Equity (as reported)1,046,575
Total Stockholder Equity (calculated)1,046,575
+/-0
Other
Cash and Short Term Investments 611,567
Common Stock Shares Outstanding 88,307
Liabilities and Stockholders Equity 1,186,078
Net Debt -606,588
Net Working Capital 1,027,773
Short Long Term Debt Total 4,979



Balance Sheet

All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-30
> Total Assets 
0
707,976
0
638,797
610,921
1,140,483
1,108,664
1,063,727
1,032,266
1,393,042
1,314,435
1,275,267
1,239,598
1,183,332
1,142,552
1,099,856
1,076,101
1,050,313
1,006,027
973,489
935,222
897,730
846,800
794,585
905,577
858,307
1,154,934
1,086,561
1,242,237
1,186,078
1,186,0781,242,2371,086,5611,154,934858,307905,577794,585846,800897,730935,222973,4891,006,0271,050,3131,076,1011,099,8561,142,5521,183,3321,239,5981,275,2671,314,4351,393,0421,032,2661,063,7271,108,6641,140,483610,921638,7970707,9760
   > Total Current Assets 
0
699,485
0
630,616
600,451
1,130,486
1,099,024
1,053,695
1,022,346
1,382,064
1,271,841
1,234,306
1,199,426
1,144,389
1,105,867
1,064,420
1,040,011
1,008,360
965,921
934,963
897,976
861,786
807,957
757,629
870,904
820,841
1,120,973
1,055,234
1,213,947
1,152,739
1,152,7391,213,9471,055,2341,120,973820,841870,904757,629807,957861,786897,976934,963965,9211,008,3601,040,0111,064,4201,105,8671,144,3891,199,4261,234,3061,271,8411,382,0641,022,3461,053,6951,099,0241,130,486600,451630,6160699,4850
       Cash And Cash Equivalents 
0
692,530
0
622,063
590,677
1,110,367
1,078,746
1,041,740
1,008,522
917,307
1,255,567
1,218,437
1,170,178
1,112,770
1,077,255
1,049,934
1,036,295
999,940
960,466
929,570
891,525
848,405
800,846
751,750
863,159
805,386
1,106,000
1,042,111
697,785
611,567
611,567697,7851,042,1111,106,000805,386863,159751,750800,846848,405891,525929,570960,466999,9401,036,2951,049,9341,077,2551,112,7701,170,1781,218,4371,255,567917,3071,008,5221,041,7401,078,7461,110,367590,677622,0630692,5300
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
29,248
28,494
28,612
14,486
3,716
5,601
5,455
5,393
0
9,044
0
0
0
0
0
0
0
0
000000009,04405,3935,4555,6013,71614,48628,61228,49429,248000000000000
       Other Current Assets 
0
6,955
0
8,553
9,774
20,119
20,278
11,955
13,824
464,757
16,274
15,869
29,248
31,619
28,612
14,486
3,716
8,420
5,455
5,393
6,451
13,381
7,111
5,879
7,745
1
14,973
13,123
516,162
541,172
541,172516,16213,12314,97317,7455,8797,11113,3816,4515,3935,4558,4203,71614,48628,61231,61929,24815,86916,274464,75713,82411,95520,27820,1199,7748,55306,9550
   > Long-term Assets 
0
8,491
0
8,181
10,470
9,997
9,639
10,032
9,920
10,978
42,594
40,962
40,172
38,943
36,686
35,437
36,089
41,954
40,106
38,526
37,246
35,944
38,843
36,957
34,672
37,466
33,961
31,326
28,290
33,339
33,33928,29031,32633,96137,46634,67236,95738,84335,94437,24638,52640,10641,95436,08935,43736,68638,94340,17240,96242,59410,9789,92010,0329,6399,99710,4708,18108,4910
       Property Plant Equipment 
0
5,644
0
5,305
7,580
7,092
6,720
7,191
7,065
9,289
40,817
39,132
38,304
37,135
34,838
33,539
34,136
39,939
38,078
36,355
35,051
33,747
36,648
34,756
32,475
35,264
31,771
29,107
26,088
31,126
31,12626,08829,10731,77135,26432,47534,75636,64833,74735,05136,35538,07839,93934,13633,53934,83837,13538,30439,13240,8179,2897,0657,1916,7207,0927,5805,30505,6440
       Other Assets 
0
0
0
0
0
0
19,279
0
0
0
0
0
1,868
1,809
1,847
1,897
72,179
2,013
2,028
2,171
2,195
2,196
2,195
-1
1
596
577
1
554
0
055415775961-12,1952,1962,1952,1712,0282,01372,1791,8971,8471,8091,8680000019,279000000
> Total Liabilities 
0
647,216
0
574,601
546,841
504,349
457,111
407,053
349,735
375,306
283,070
275,726
248,331
208,835
164,186
159,381
155,938
143,014
127,425
129,165
128,037
109,054
101,670
94,634
68,177
72,065
69,560
92,556
113,524
139,503
139,503113,52492,55669,56072,06568,17794,634101,670109,054128,037129,165127,425143,014155,938159,381164,186208,835248,331275,726283,070375,306349,735407,053457,111504,349546,841574,6010647,2160
   > Total Current Liabilities 
0
643,080
0
570,465
542,705
498,862
451,623
401,566
344,248
342,787
225,192
219,427
193,624
149,222
107,301
104,235
102,097
108,721
94,551
97,152
97,588
101,268
95,820
91,194
66,831
70,883
68,843
91,028
112,340
124,966
124,966112,34091,02868,84370,88366,83191,19495,820101,26897,58897,15294,551108,721102,097104,235107,301149,222193,624219,427225,192342,787344,248401,566451,623498,862542,705570,4650643,0800
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
6,149
6,213
6,277
6,439
6,380
6,475
6,870
7,141
7,223
7,890
8,030
8,092
8,316
8,760
8,820
8,857
7,203
4,588
1,866
2,827
2,8271,8664,5887,2038,8578,8208,7608,3168,0928,0307,8907,2237,1416,8706,4756,3806,4396,2776,2136,1490000000000
       Accounts payable 
0
11,736
0
8,249
0
7,586
0
0
0
14,808
0
0
0
8,218
0
0
0
14,311
7,710
10,266
11,537
11,818
0
7,215
11,143
21,491
26,368
43,548
59,487
73,290
73,29059,48743,54826,36821,49111,1437,215011,81811,53710,2667,71014,3110008,21800014,8080007,58608,249011,7360
       Other Current Liabilities 
0
631,344
0
562,216
542,705
491,276
451,623
401,566
344,248
327,979
219,043
213,214
187,347
134,565
100,921
97,760
95,227
87,269
87,328
89,262
89,558
81,358
87,504
82,434
58,011
40,535
61,640
86,440
110,474
48,849
48,849110,47486,44061,64040,53558,01182,43487,50481,35889,55889,26287,32887,26995,22797,760100,921134,565187,347213,214219,043327,979344,248401,566451,623491,276542,705562,2160631,3440
   > Long-term Liabilities 
0
4,136
0
4,136
4,136
5,487
5,488
5,487
5,487
32,519
57,878
56,299
54,707
59,613
56,885
55,146
53,841
34,293
32,874
32,013
30,449
7,786
5,850
3,440
1,346
1,182
717
1,528
1,184
14,537
14,5371,1841,5287171,1821,3463,4405,8507,78630,44932,01332,87434,29353,84155,14656,88559,61354,70756,29957,87832,5195,4875,4875,4885,4874,1364,13604,1360
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
13,627
12,207
11,347
9,783
7,785
5,850
3,440
1,345
1,182
717
1,529
1,183
0
01,1831,5297171,1821,3453,4405,8507,7859,78311,34712,20713,62700000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
32,520
38,685
38,685
38,685
38,686
20,666
20,667
20,666
20,666
1
0
0
1
0
0
-1
0
0
00-100100120,66620,66620,66720,66638,68638,68538,68538,68532,520000000000000
> Total Stockholder Equity
0
60,760
0
64,196
64,080
636,134
651,553
656,674
682,531
1,017,736
1,031,365
999,541
991,267
974,497
978,366
940,475
920,163
907,299
878,602
844,324
807,185
788,676
745,130
699,951
837,400
786,242
1,085,374
994,005
1,128,713
1,046,575
1,046,5751,128,713994,0051,085,374786,242837,400699,951745,130788,676807,185844,324878,602907,299920,163940,475978,366974,497991,267999,5411,031,3651,017,736682,531656,674651,553636,13464,08064,196060,7600
   Common Stock
0
105
0
105
0
1,761
0
0
0
1,761
0
0
991,267
1,761
978,366
940,475
920,163
1,761
878,602
844,324
807,185
1,761
745,130
699,951
837,400
1,763
1,764
1,765
1,766
1,766
1,7661,7661,7651,7641,763837,400699,951745,1301,761807,185844,324878,6021,761920,163940,475978,3661,761991,267001,7610001,761010501050
   Retained Earnings Total Equity000000000000000000000000000000
   Accumulated Other Comprehensive Income 000000000000000000000000000000
   Capital Surplus 000000000000000000000000000000
   Treasury Stock000000000000000000000000000000
   Other Stockholders Equity 
0
958
0
958
0
560,976
0
0
0
560,976
0
0
0
560,976
978,366
940,475
920,163
560,976
878,602
844,324
807,185
560,976
745,130
699,951
837,400
566,959
1,083,610
992,240
1,126,947
1,044,809
1,044,8091,126,947992,2401,083,610566,959837,400699,951745,130560,976807,185844,324878,602560,976920,163940,475978,366560,976000560,976000560,976095809580



Balance Sheet

All numbers in thousands.




Cash Flow

Currency in SEK. All numbers in thousands.




Income Statement

Currency in SEK. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue615,995
Cost of Revenue-269,679
Gross Profit346,316346,316
 
Operating Income (+$)
Gross Profit346,316
Operating Expense-89,627
Operating Income256,689256,689
 
Operating Expense (+$)
Research Development89,627
Selling General Administrative0
Selling And Marketing Expenses0
Operating Expense89,62789,627
 
Net Interest Income (+$)
Interest Income20,657
Interest Expense-10,382
Other Finance Cost-8,665
Net Interest Income18,940
 
Pretax Income (+$)
Operating Income256,689
Net Interest Income18,940
Other Non-Operating Income Expenses0
Income Before Tax (EBT)276,486236,892
EBIT - interestExpense = 246,307
276,486
239,631
Interest Expense10,382
Earnings Before Interest and Taxes (EBIT)256,689286,868
Earnings Before Interest and Taxes (EBITDA)275,117
 
After tax Income (+$)
Income Before Tax276,486
Tax Provision-35,654
Net Income From Continuing Ops258,615240,832
Net Income229,249
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses359,306
Total Other Income/Expenses Net19,797-18,940
 

Technical Analysis of Bioarctic
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Bioarctic. The general trend of Bioarctic is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Bioarctic's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of BioArctic AB (publ).

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 209.00 < 237.60 < 245.40.

The bearish price targets are: 191.50 > 116.70 > 110.60.

Tweet this
BioArctic AB (publ) Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of BioArctic AB (publ). The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

BioArctic AB (publ) Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of BioArctic AB (publ).

BioArctic AB (publ) Daily Moving Average Convergence/Divergence (MACD) ChartBioArctic AB (publ) Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of BioArctic AB (publ). The current adx is .

BioArctic AB (publ) Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of BioArctic AB (publ).

BioArctic AB (publ) Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of BioArctic AB (publ).

BioArctic AB (publ) Daily Relative Strength Index (RSI) ChartBioArctic AB (publ) Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of BioArctic AB (publ).

BioArctic AB (publ) Daily Stochastic Oscillator ChartBioArctic AB (publ) Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of BioArctic AB (publ).

BioArctic AB (publ) Daily Commodity Channel Index (CCI) ChartBioArctic AB (publ) Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of BioArctic AB (publ).

BioArctic AB (publ) Daily Chande Momentum Oscillator (CMO) ChartBioArctic AB (publ) Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of BioArctic AB (publ).

BioArctic AB (publ) Daily Williams %R ChartBioArctic AB (publ) Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of BioArctic AB (publ).

BioArctic AB (publ) Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of BioArctic AB (publ).

BioArctic AB (publ) Daily Average True Range (ATR) ChartBioArctic AB (publ) Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of BioArctic AB (publ).

BioArctic AB (publ) Daily On-Balance Volume (OBV) ChartBioArctic AB (publ) Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of BioArctic AB (publ).

BioArctic AB (publ) Daily Money Flow Index (MFI) ChartBioArctic AB (publ) Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for BioArctic AB (publ).

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-22STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-23STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-11-24DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-27MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-11-29MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-11-30DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-01SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-05DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-07STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-08CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-11SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-12STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-18RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-19MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-27WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-04CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-05CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-09CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-12CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-17WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-18STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-24STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-29STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-31SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-01SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-02MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-06MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-08STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-14RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-20STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-21STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-28CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-29STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-07CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-11WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-03-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-18SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-19STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-21DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-03-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-27STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-02CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-05STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-11CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).

6.3. Candlestick Patterns

BioArctic AB (publ) Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of BioArctic AB (publ) based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose214.600
Total1/1 (100.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Bioarctic with someone you think should read this too:
  • Are you bullish or bearish on Bioarctic? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Bioarctic? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about BioArctic AB (publ)

I send you an email if I find something interesting about BioArctic AB (publ).


Comments

How you think about this?

Leave a comment

Stay informed about BioArctic AB (publ).

Receive notifications about BioArctic AB (publ) in your mailbox!